OVERVIEW OF THE WINTER 2012 COMPARABILITY STUDY
For the Winter 2012 Comparability Study of VitDQAP (Exercise 5), control and human serum study samples were distributed to participants for evaluation. SRM 2972, which is comprised of separate ethanolic solutions with known concentrations of 25-hydroxyvitamin D 2 (25(OH)D 2 ) and 25-hydroxyvitamin D 3 (25(OH)D 3 ), was provided as a control material for assay calibration or verification. Participants were asked to provide single results for each of these solutions. In addition, participants were asked to determine concentration values for 25(OH) There were a total of 51 participants and 57 datasets (six participants provided data for two different methods) in the Winter 2012 study. Seventeen of the datasets originated from immunoassay (IA) techniques, including three from enzyme immunoassay (EIA), eight from chemiluminescence immunoassay (CLIA), and six from radioimmunoassay (RIA). Appendix A-1 summarizes the immunoassay methods used by the participants. Forty of the datasets originated from liquid chromatographic (LC) methods; of those, 32 were from LC with tandem mass spectrometric detection (LC-MS/MS), one was from LC-MS (orbitrap), and seven were from LC with ultraviolet absorbance detection (LC-UV). A summary of the LC methods used by the participants may be found in Appendices A-2 and A-3. From here, LC-MS/MS and LC-MS are collectively referred to as LC-MS n .
The raw data received from all participants are summarized in Appendix B. SRM 1950, SRM 972a L2, and SRM 968d L1 contain low levels of 25(OH)D 2 (reported participant values ranging from 0.2 ng/mL to 1.7 ng/mL), and most of the LC labs indicated this analyte was below their quantitation limit of <1 ng/mL to <7 ng/mL. Therefore, the 25(OH)D Total values reported in Appendix B are the same as the 25(OH)D 3 values in the serum and plasma materials for the majority of LC participants.
Appendix B also provides the summarized results from the National Institute of Standards and Technology (NIST) for each of the serum materials. The 25(OH)D 2 in SRM 968d L1 was below the quantitation limit (≈ 0.5 ng/mL) for the NIST method.
WINTER 2012 COMPARABILITY STUDY RESULTS AND DISCUSSION

25(OH)D 2 and 25(OH)D 3 in the control solutions (SRM 2972)
Participants were asked to analyze the control materials to qualify their assays prior to measuring the study materials. A summary of the individual participant data for 25(OH)D 2 and 25(OH)D 3 in the SRM 2972 control solutions is provided in Table 1 . Of the 57 datasets received for the Winter 2012 study, only 36 reported values for the ethanolic controls; of those, three were from immunoassay methods and 33 were from LC methods. Overall, the control solutions appeared more compatible with the LC methods, and several of the immunoassay participants reported that the calibration solutions were not compatible with their method and did not provide values.
The community results are summarized at the bottom of Table 1 for all reported methods, the LC methods only, and the LC-MS n methods only. The community results include the total number of quantitative values reported (N), the median value for each analyte, the MADe (the median absolute deviation estimate, a robust estimate of the standard deviation), and the percent coefficient of variation (CV%). The consensus results using robust statistics (i.e., median and MADe) were not calculated for the data from the IA methods because of the limited number of data reported.
The control materials were characterized at NIST using both gravimetry and LC-MS. Table 1 presents the NIST certified values with expanded uncertainties corresponding to 95% confidence for SRM 2972. Participants were provided these values both on the shipping package and within the data reporting sheet so that they could qualify their methods prior to analyzing the study samples. Figure 1 . The results from immunoassay methods are displayed with closed red circles (), and the results from the LC-based methods are displayed with closed black squares (■).
From the single reported values for all LC datasets, the consensus median and the consensus variability (2 × MADe) were determined (reported in Table 1 ). In Figure 1 , the solid lines () represent the consensus median and the dashed lines (-----) represent the approximate 95% confidence interval (2 × MADe) for the LC datasets; the laboratories with results that fall between the two dashed lines are within the consensus variability.
The grey-shaded bar in Figure 1 represents the interval in which NIST believes the "true value" exists for these solutions (i.e., NIST value ± approximately 95% confidence intervals (U 95 )). The community results are summarized at the bottom of the table for all reported methods, the immunoassay methods only, the LC methods only, and the LC-MS n methods only. These summarized results include N, the median value, the MADe, and the CV%. Figure 2 . The results from immunoassay methods are displayed with closed red circles (), and the results from the LCbased methods are displayed with closed black squares (■). Each figure also has a legend that indicates which individual methods were used to obtain the reported values: CLIA, EIA, RIA, LC-MS n , or LC-UV.
From the average values for all datasets for a given technique (IA or LC), the consensus median and the consensus variability (2 × MADe) were determined (reported in Table 2 ). For each of the techniques within both graphs, the solid lines () represent the consensus median and the dashed lines (-----) represent the consensus variability (2 × MADe).
For the IA data for material SRM 1950, the consensus variability based on MADe is an overestimation of the 95% confidence limits about the median. The non-Gaussian data distribution contributes to a relatively wide range for the central 50% of this data, resulting in a large MADe (Figure 2 ). Since the consensus variability is not well-described with a MADe estimation, a meaningful assessment of the consensus range, the outlying results, and the agreement with the NIST value is hindered for the IA results for SRM 1950.
For the LC datasets for SRM 1950 and for both the LC and IA datasets for SRM 972a L2 and SRM 968d L1, the laboratories with results that fall between the two dashed lines are within the consensus variability area for their technique (IA or LC). The grey-shaded bar for each figure represents the NIST value and its associated uncertainty (i.e., value ± U 95 ). NIST believes that the "true" value for each material lies within this interval. When this bar is not within the consensus range, then there may be method bias.
Specific results as assessed from Figure 2 are summarized below.
SRM 1950
• For the IA results, the data appear to be non-normally distributed, and the consensus variability is not well-described with a MADe estimation.
• For the LC results, all but five datasets are within the consensus variability range.
• The consensus median value for the IA results is higher than the consensus median value for the LC results; both LC and IA median values are higher than the NIST expanded uncertainty range (grey-shaded bar).
• The NIST expanded uncertainty range (grey-shaded bar) falls within the consensus variability range for LC and overlaps the IA data range
SRM 972a L2
• For the IA results, all but one dataset are within the consensus variability range when the average results are considered.
• For the LC results, all but seven datasets are within the consensus variability range when the average results are considered.
• The consensus median values are comparable for both the IA results and LC results and are slightly higher than the NIST expanded uncertainty range (grey-shaded bar).
• The NIST expanded uncertainty range (grey-shaded bar) falls within the consensus variability ranges for both IA and LC.
SRM 968d L1
• For the IA results, all datasets are within the consensus variability range.
• For the LC results, nine datasets are outside of the consensus variability range (four LC-MS n , five LC-UV).
• The NIST expanded uncertainty range (grey-shaded bar) falls within the consensus variability range for LC and overlaps the consensus variability range for IA.
Overall, the results for the three study materials are consistent, with the majority of the participant values higher than the NIST value. In addition, the consensus variability is similar but relatively high for the three materials, ranging from 9.3% to 11% when all methods are considered ( Table 2) . Similar trends have also been observed for many of the study materials evaluated in previous studies of the VitDQAP. A goal of the program is to achieve better agreement between the participant consensus median value and the NIST value and to better understand the sources of bias between the results. In addition, a major goal of VitDQAP is to reduce the consensus variability to better represent the community's measurement capability while also recognizing that a "fit-forpurpose" variability level may exist.
It is notable that the NIST method separates 25(OH)D 3 and its 3-epimer, 3-epi-25(OH)D 3 , which was detected in all study materials but quantitated in SRM 972a L2 only (1.29 ng/mL ± 0.06 ng/mL). . Laboratory results that are within the consensus range for both study materials are within the blue consensus boxes. Conversely, laboratory results that fall outside of (or on the edge of) either of the consensus boxes are not included in the consensus ranges and are highlighted with their laboratory code numbers (numbers 186, 180, 225, 245, 189, 216, 218b, 228, 086b and 185a) . The NIST value for this material (18.9 ng/mL) is denoted with a red diamond symbol (), and the Youden line (y=x) centered on the NIST value is illustrated by a red line () across the magnitude of the y-and xaxis, respectively. The Youden line runs through both the IA and LC consensus boxes for these materials.
For the second Youden plot (Panel B), the results for SRM 972a L2 are evaluated with respect to a 10% range relative to the NIST value for this material (18.9 ng/mL). Laboratory results that fall outside of this range are indicative of non-repeatable measurement performance for this material and are highlighted with their laboratory code numbers (numbers 186, 221b, 194, 209, 184, 225, 245, 086b and 185a) . In general, the combined results for vial B and vial D from these laboratories had a relative standard deviation ≥ 10% ( Table 2 ). The relative distance of the individual laboratory results from the Youden line (y=x) is also indicative of the relative level of imprecision between the two results.
. 
Correlation of 25(OH)D in SRM 1950, SRM 972a L2, and W012-3 with Clinical Ranges
The current guidance regarding 25(OH)D concentrations and human health (obtained from the NIH website) is presented in Table 3 . • The NIST value (25.3 ng/mL ± 0.8 ng/mL) is in the adequate 25(OH)D concentration range.
SRM 972a L2
• The participant results are almost equally split between the inadequate and adequate 25(OH)D concentration ranges.
• The NIST value (18.9 ng/mL ± 0.4 ng/mL) is in the inadequate 25(OH)D concentration range.
SRM 968d L1
• The range of participant results for SRM 968d L1 is larger than for the other materials.
• The majority of participant results are in the inadequate 25(OH)D concentration range, but several also reported deficient and adequate concentration values.
• The NIST value (12.4 ng/mL ± 0.3 ng/mL) is in the inadequate 25(OH)D concentration range.
The consensus CV% of the participant results from all methods was ≈ 10 % for the study materials ( Table 2) CLIA n/a n/a n/a n/a n/a n/a n/a n/a 24. RIA n/a n/a n/a n/a n/a n/a n/a n/a 28.7 20.6 13.3 21.2 n/r 323.1 086a CLIA n/a n/a n/a n/a n/a n/a n/a n/a 32.9 21.6 14.5 23.3 n/r n/r 086b RIA n/a n/a n/a n/a n/a n/a n/a n/a 33. CLIA n/a n/a n/a n/a n/a n/a n/a n/a 26.7 19.9 17.0 18.5 n/r n/r 180 RIA n/a n/a n/a n/a n/a n/a n/a n/a 25. CLIA n/a n/a n/a n/a n/a n/a n/a n/a 33. CLIA n/a n/a n/a n/a n/a n/a n/a n/a 31. RIA n/a n/a n/a n/a n/a n/a n/a n/a 27. CLIA n/a n/a n/a n/a n/a n/a n/a n/a 28. EIA n/a n/a n/a n/a n/a n/a n/a n/a 31. RIA n/a n/a n/a n/a n/a n/a n/a n/a 25.8 18.9 14.6 18.8 278.1 386.9 201 EIA n/a n/a n/a n/a n/a n/a n/a n/a 33. RIA n/a n/a n/a n/a n/a n/a n/a n/a 26.8 22.1 15.1 19.6 230.0 294.3 210b CLIA n/a n/a n/a n/a n/a n/a n/a n/a 30. CLIA n/a n/a n/a n/a n/a n/a n/a n/a 26. CLIA n/a n/a n/a n/a n/a n/a n/a n/a 27.8 17. *n/a = not applicable (for immunoassay methods); n/r = not reported; n/d = not detected; < X = less than a reported quantitation limit of X 
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